Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs 10X Genomics Inc (TXG) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs 10X Genomics Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $22.15, while 10X Genomics Inc trades at $45.9 (market cap $5.81B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

BOILTXG
Sector
Leveraged / InverseHealth
52-Week High
$98.62$45.80
52-Week Low
$21.86$11.34
Market Cap
$5.81B
Enterprise Value
$5.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.

The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.

10X Genomics Inc

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG